A. van der Gaast

发表

Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

D. Richel, J. V. van Lanschot, V. Oppedijk, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

E W Steyerberg, M C C M Hulshof, E. Steyerberg, 2012, The New England journal of medicine.

Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study

P. Siersema, H. van Dekken, K. Muller, 2006, British Journal of Cancer.

Oesophageal cancer: exploring controversies overview of experts’ opinions of Austria, Germany, France, Netherlands and Switzerland

T. Ruhstaller, C. Mariette, J. V. van Lanschot, 2015, Radiation oncology.

Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

J. Verweij, L. van Zuylen, A. Sparreboom, 2002, European journal of cancer.

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

V. Diéras, A. van der Gaast, H. Fontaine, 2014, British Journal of Cancer.

Neoadjuvant treatment in esophageal cancer—established treatments and new developments reviewed

A. van der Gaast, A. Gaast, B. Mostert, 2021, Annals of Esophagus.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

J. Verweij, A. Sparreboom, R. Mathijssen, 2006, The oncologist.

Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients With Potentially Curable Esophageal Cancer

R. Boellaard, M. Cuesta, P. Bossuyt, 2011, Annals of surgery.

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 2003, British Journal of Cancer.

The optimal neoadjuvant treatment of locally advanced esophageal cancer.

J. Nuyttens, J. V. van Lanschot, A. van der Gaast, 2019, Journal of thoracic disease.

Neoadjuvant chemoradiotherapy for resectable oesophageal cancer.

J. Nuyttens, R. Valkema, J. Nuyttens, 2018, Best practice & research. Clinical gastroenterology.

Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The rotterdam experience

H. van Dekken, K. Muller, J. Poley, 2009, Journal of surgical oncology.

Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer

D. Nieboer, M. Sosef, R. Valkema, 2019, Annals of surgery.

A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy

B. V. van Rhijn, A. van der Gaast, G. Mickisch, 2002, Cancer Chemotherapy and Pharmacology.

Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy

D. van Klaveren, E. Steyerberg, K. Biermann, 2017, Annals of surgery.

Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction.

V. Gebski, J. Roth, Jian-Hua Fu, 2021, European journal of cancer.

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study

K. Lam, S. Law, R. Valkema, 2020, BMC Cancer.

Chemotherapy aNd chemoradiotherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial

J. Nuyttens, A. van der Gaast, S. Lagarde, 2022, Contemporary clinical trials communications.

Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.

P. Siersema, R. Hoekstra, M. Polée, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Cancer Chemotherapy and Pharmacology.

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.

E. Steyerberg, R. van Hillegersberg, F. Vleggaar, 2018, The Lancet. Oncology.

Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer.

R. Valkema, K. Biermann, J. V. van Lanschot, 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

What is the role of dose-dense therapy?

J. Verweij, I. Vergote, H. V. van Doorn, 2005, International Journal of Gynecologic Cancer.

Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer.

A. W. Boersma, M. Flens, F. Bosman, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.

B. G. Blijenberg, A. van der Gaast, F. Cornillie, 1994, British Journal of Cancer.

The potential of statins as part of anti-cancer treatment.

S. Sleijfer, J. Verweij, A. van der Gaast, 2005, European journal of cancer.

Pattern of recurrence in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer

J. Nuyttens, J. V. van Lanschot, A. van der Gaast, 2021, BJS open.

Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study

E. Steyerberg, G. Hanna, J. Reynolds, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.

A. van der Gaast, E. Van Loon, T. Splinter, 1993, European journal of cancer.

Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects.

P. Dagnelie, G. Swart, A. van der Gaast, 2000, Metabolism: clinical and experimental.

Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment

P. de Bruijn, W. Loos, T. van Gelder, 2008, Cancer Chemotherapy and Pharmacology.

Experiences and expectations of patients after oesophageal cancer surgery: an explorative study.

E. Kuipers, E. Steyerberg, M. Essink‐bot, 2006, European journal of cancer care.

Effectiveness of neoadjuvant chemoradiotherapy for early-stage esophageal cancer.

J. V. van Lanschot, A. van der Gaast, M. Hulshof, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

13-cis-retinoic acid and alpha-interferon in advanced squamous cell cancer of the oesophagus.

A. van der Gaast, T. Splinter, T. Kok, 1997, European journal of cancer.

Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction

P. Siersema, C. Lamers, A. van der Gaast, 2015, Journal of cachexia, sarcopenia and muscle.

Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement

L. Koppert, H. van Dekken, A. van der Gaast, 2009, Journal of surgical oncology.

Causes and treatment of recurrent dysphagia after self-expanding metal stent placement for palliation of esophageal carcinoma.

E. Kuipers, E. Steyerberg, P. Siersema, 2004, Endoscopy.

Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas

T. Splinter, A. van der Gaast, J. Verwey, 1990, Cancer.

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial

E. Steyerberg, S. Polinder, P. Siersema, 2018, BMC Cancer.

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

J. Verweij, L. van Zuylen, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Elevated serum tumor markers in patients with testicular cancer after induction chemotherapy due to a reservoir of markers in cystic differentiated mature teratoma.

T. Splinter, A. van der Gaast, A. Gaast, 1991, The Journal of urology.

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.

J. Verweij, M. Polée, A. van der Gaast, 2002, European journal of cancer.

Reply to E. C. Smyth et al.

V. Oppedijk, A. van der Gaast, M. Hulshof, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: effects on lipolysis and lipid oxidation.

P. Dagnelie, G. Swart, A. van der Gaast, 2000, Clinical nutrition.

Induction chemotherapy followed by surgery for advanced oesophageal cancer.

R. Mathijssen, K. Biermann, J. V. van Lanschot, 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial

E. Steyerberg, M. Cuesta, J. Plukker, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Carcinoma of unknown primary: identification of a treatable subset?

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy: Prognostic and Therapeutic Impact on Survival

E. Steyerberg, G. Hospers, F. T. ten Kate, 2014, Annals of surgery.

What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.

A. van der Gaast, T. Splinter, T. Kok, 1992, Seminars in oncology.

What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposide.

A. van der Gaast, T. Splinter, T. Kok, 1992, Seminars in oncology.

Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study)

E. D. Geijsen, J. Nuyttens, J. V. van Hooft, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.

J. Verweij, A. van der Gaast, G. Stoter, 1988, European Journal of Cancer and Clinical Oncology.

Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial

P. Siersema, W. Dinjens, F. T. ten Kate, 2011, BMC Cancer.

[Guideline 'Diagnosis and treatment of oesophageal carcinoma'].

L. Stassen, P. Siersema, D. Richel, 2006, Nederlands tijdschrift voor geneeskunde.

[Palliative treatment in patients with oesophagus carcinoma].

E. Kuipers, P. Siersema, E. Verschuur, 2005, Nederlands tijdschrift voor geneeskunde.

Intrapericardial instillation of bleomycin in the management of malignant pericardial effusion.

A. van der Gaast, T. Splinter, T. Kok, 1989, European Journal of Cancer and Clinical Oncology.

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

E. Steyerberg, M. Cuesta, C. Punt, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

E. Steyerberg, M. Cuesta, C. Punt, 2015, The Lancet. Oncology.

Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial

L. Stassen, E. Kuipers, E. Steyerberg, 2008, British Journal of Cancer.

Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.

W. Hop, J. Verweij, A. van der Gaast, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of cisplatin plus 24-hour infusion of ifosfamide in advanced malignant melanoma.

J. Verweij, A. van der Gaast, G. Stoter, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

P 53 and SOX 2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to emoradiotherapy Neoadjuvant

L. Looijenga, M. Bruno, K. Biermann, 2016 .

P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.

L. Looijenga, M. Bruno, K. Biermann, 2017, Annals of surgery.

Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer: A Prospective Randomized Controlled Trial

W. Hop, J. Jeekel, G. Kazemier, 2008, Annals of surgery.

Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer.

D. Richel, J. Nuyttens, W. Vervenne, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS)

J. Lagergren, P. Lagergren, A. van der Gaast, 2018, Annals of Surgical Oncology.

Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.

E. Kuipers, E. Steyerberg, M. Peppelenbosch, 2017, The Cochrane database of systematic reviews.

The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.

S. Sleijfer, F. D. de Jongh, A. van der Gaast, 2010, European journal of cancer.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

J Verweij, J. Verweij, A. Sparreboom, 1999, Anti-cancer drugs.

A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer

J. Verweij, A. Sparreboom, R. Hoekstra, 2004, Clinical Cancer Research.

Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer

M. Cuesta, J. Plukker, G. Nieuwenhuijzen, 2016, Annals of Surgical Oncology.

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

C. Bucana, J. Verweij, I. Fidler, 2005, Clinical Cancer Research.

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer.

B. G. Blijenberg, W. Hop, A. van der Gaast, 1994, European journal of cancer.

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

W. Hop, M. Polée, A. van der Gaast, 2003, British Journal of Cancer.

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients

R. Mathijssen, A. van der Gaast, F. D. de Man, 2019, Cancers.

Self-expanding metal stents for complicated and recurrent esophagogastric cancer.

E. Steyerberg, P. Siersema, A. van der Gaast, 2001, Gastrointestinal endoscopy.

National compliance to an evidence-based multidisciplinary guideline on pancreatic and periampullary carcinoma.

L. Veerbeek, M. Bruno, A. van der Gaast, 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Long term survival of small cell lung cancer patients after chemotherapy.

P. Postmus, T. Splinter, A. van der Gaast, 1993, British Journal of Cancer.

Complete Remission of a Brain Metastasis to Third‐Line Hormonal Treatment with Megestrol Acetate

J. Verweij, J. Alexieva-Figusch, A. van der Gaast, 1990, American journal of clinical oncology.

NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)

R. Boellaard, P. Bossuyt, O. Hoekstra, 2008, BMC medical physics.

Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.

D. Nieboer, E. Steyerberg, K. Biermann, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.

A. van der Gaast, G. Stoter, H. Tilanus, 1996, British Journal of Cancer.

Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer

J. Verweij, M. Polée, A. van der Gaast, 2002, British Journal of Cancer.

Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery

D. van Klaveren, E. Steyerberg, J. V. van Lanschot, 2016, The British journal of surgery.

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

M. Piccart, J. Wanders, J. Verweij, 2002, European journal of cancer.

Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer.

P. Dagnelie, T. Stijnen, A. van der Gaast, 2000, Journal of the National Cancer Institute.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.

H. Groen, E. D. de Vries, J. Verweij, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.

D. Aust, J. Ajani, M. Ychou, 2012, European journal of cancer.

Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma.

M. Essink‐bot, K. Muller, A. van der Gaast, 2008, International journal of radiation oncology, biology, physics.

Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus

A. van der Gaast, G. Stoter, P. Siersema, 2001, Anti-cancer drugs.

WITHDRAWN: Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction.

E. Kuipers, E. Steyerberg, P. Siersema, 2010, The Cochrane database of systematic reviews.

Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer

Hester F. Lingsma, E. Steyerberg, M. Sosef, 2021, Trials.

Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients

P. Dagnelie, A. van der Gaast, S. Burgers, 2003, Anti-cancer drugs.

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

E. Steyerberg, M. Cuesta, M. Sprangers, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nurse-led follow-up at home vs. conventional medical outpatient clinic follow-up in patients with incurable upper gastrointestinal cancer: a randomized study.

E. Kuipers, E. Steyerberg, P. Siersema, 2014, Journal of pain and symptom management.

Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer.

M. Cozijnsen, R. Hoekstra, W. van Putten, 1991, British Journal of Cancer.

Growing teratoma syndrome successfully treated with lymphoblastoid interferon.

A. van der Gaast, T. Splinter, T. Kok, 1991, European urology.

A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.

H. Groen, J. Gietema, W. Loos, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Problems and Needs in Patients With Incurable Esophageal and Pancreaticobiliary Cancer: A Descriptive Study

E. Kuipers, E. Steyerberg, P. Siersema, 2015, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study

K. Lam, S. Law, R. Valkema, 2020, BMC Cancer.

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)

E. Steyerberg, H. van Dekken, K. Muller, 2008, BMC surgery.

The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands

E. Kuipers, E. Steyerberg, P. Siersema, 2006, British Journal of Cancer.

Phase II study of carboplatin and etoposide as a first line regimen in patients with metastatic breast cancer.

M. Bontenbal, A. van der Gaast, A. Planting, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oesophageal cancer: exploring controversies overview of experts’ opinions of Austria, Germany, France, Netherlands and Switzerland

T. Ruhstaller, C. Mariette, J. V. van Lanschot, 2015, Radiation oncology.

Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Review of Meta-Analyses

Ewout W. Steyerberg, Hugo W. Tilanus, E. Steyerberg, 2009, World Journal of Surgery.

Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial

E. Steyerberg, S. Polinder, P. Siersema, 2018, BMC Cancer.

Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy Increases Histopathological Response Without Affecting Survival in Patients With Esophageal or Junctional Cancer

E. Steyerberg, F. T. ten Kate, K. Biermann, 2014, Annals of surgery.

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study

A. van der Gaast, E. van Meerten, F. Eskens, 2007, British Journal of Cancer.

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma

V. Gebski, J. Pignon, P. Schlag, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and Pharmacokinetic Study of the Dolastatin 10 Analogue TZT-1027, Given on Days 1 and 8 of a 3-Week Cycle in Patients with Advanced Solid Tumors

J. Wanders, J. Verweij, M. D. de Jonge, 2005, Clinical Cancer Research.

Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer

M. Sprangers, J. Heisterkamp, J. V. van Lanschot, 2019, Annals of Surgical Oncology.

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours

J. Verweij, H. Burger, M. D. de Jonge, 2010, British Journal of Cancer.

Cure of Barrett's carcinoma by ifosfamide chemotherapy.

E. Kuipers, P. Siersema, H. van Dekken, 2003, European journal of gastroenterology & hepatology.

Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study

Hugo W. Tilanus, A. van der Gaast, P. van Hagen, 2013, International Journal of Clinical Oncology.

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

F. van Coevorden, K. Sikorska, J. V. van Sandick, 2018, The Lancet. Oncology.

Nurse-led follow-up at home vs. conventional medical outpatient clinic follow-up in patients with incurable upper gastrointestinal cancer: a randomized study.

E. Kuipers, E. Steyerberg, P. Siersema, 2014, Journal of pain and symptom management.

P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.

A. van der Gaast, M. Spaander, B. Wijnhoven, 2016, Annals of surgery.

Carcinoma of unknown primary: identification of a treatable subset?

J. Verweij, S. Henzen‐Logmans, A. van der Gaast, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.

L. Looijenga, M. Bruno, K. Biermann, 2017, Annals of surgery.

5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group.

A. van der Gaast, T. Splinter, T. Kok, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.